Aims The aim of this study was to assess the risk of intra-aortic balloon counterpulsation and to identify clinical and procedural variables that would predict complications.
Introduction
The concept of intra-aortic balloon counterpulsation was introduced by Moulopoulos 35 years ago [1] , and was first employed clinically 6 years later by Kantrowitz et al. [2] . In the years since, it has become an accepted and valued clinical tool for cardiogenic shock [3] [4] [5] [6] . Since the advent of percutaneous placement [7] , intra-aortic balloon counterpulsation has been used by an increasing number of institutions familiar with interventional cardiology. In addition to cardiogenic shock, the system may be of use in a variety of other indications in the catheterization laboratory and intensive care unit, including weaning from percutaneous cardiopulmonary bypass, in ischaemic left ventricular failure, in unstable angina, in high-risk PTCA, and in prophylactic pumping in patients with myocardial infarction and successful revascularization following myocardial infarction [8] [9] [10] [11] [12] [13] [14] [15] [16] . In contrast to other cardiac assist devices with percutaneous placement such as the Hemopump [17] and cardiopulmonary bypass [18, 19] , the intra-aortic balloon is relatively easy to insert and to operate. This allows for rapid placement and routine use even in institutions not familiar with or not specializing in cardiac assist.
Since in the past intra-aortic balloon counterpulsation has been reported to have widely differing complication rates, and in view of the new elective and non-emergency indications for the system, the aim of the present study was to assess the system's risk and to identify potential predictors of complications. To this end, a wide range of clinical and procedural variables was examined in uni-and multivariate analyses.
Methods
We retrospectively analysed the data of 381 consecutive patients who received an intra-aortic balloon or in whom balloon placement was attempted between 1977 and 1995. All procedures were performed in the intensive care unit, in the catheterization laboratory, or in the emergency room of our hospital. From 1977 (the first intra-aortic balloon was implanted on 31 December 1977) to 1980, the balloons were placed surgically, following arteriotomy of the femoral artery, via a Dacron prosthesis which was sutured onto the vessel. From December 1980, all balloons were implanted percutaneously through a femoral sheath, using a modified Seldinger technique [10] and size 12 F catheters (sheath: 14 F, Kontron Instruments). From May 1987 to December 1991, 10·5 F catheters (sheath: 12·5 F, Kontron Instruments) were used, and from December 1991, only 9·5 F catheters (10 F sheath with an outer diameter of 11·5 F, Datascope Corp.) were employed. In all patients, only balloons with a volume of 40 ccm were used. If not already done before admission, all patients received a bolus of 5000 units of heparin intravenously. High dose heparinization was continued during counterpulsation (800 to 1600 IU . h 1 intravenously), and was stopped 3 to 6 h before removal of the balloon catheter.
Potential clinical and demographic risk factors were analysed, including age, sex, peripheral vascular disease (previously known or newly diagnosed), diabetes mellitus, and previous diagnosis of systemic hypertension, hyperlipoproteinaemia, nicotine use, thrombolytic treatment at the time of insertion, and cardiogenic shock at the time of implantation. Shock was defined as a systolic aortic pressure c80 mmHg plus an additional sign of hypoperfusion, such as altered mental status/ somnolence, cyanosis/pallor, urine output <20 ml . h 1 , and/or high dose catecholamine treatment. As potential procedural risk factors, we studied the size (diameter) of the balloon catheters and sheaths as well as the length of time during which the catheters were in situ (=duration of support).
The following intra-aortic balloon-related complications were assessed: ischaemia of the ipsilateral limb resulting in removal or change of the balloon catheter, surgical intervention, or compartment syndrome; vascular injury necessitating surgical revision; bleeding at the site of implantation or arterial puncture which required transfusions or surgical intervention; central or peripheral embolic events; infection at the puncture site.
Statistics
The results were entered into a database and analysed with the statistics software package SAS 6.11 for Windows 95. The data are presented as average standard deviation. To examine the significance, the chi-square test or Fisher's Exact test was used for univariate analysis with discrete parameters, and the Wilcoxon test was employed for non-parametric variables. A P value of <0·05 was deemed significant. To compare the risk of complications in patients with a percutaneously implanted intra-aortic balloon, stepwise multivariate logistic regression analysis was performed. To be considered an independent predictor of complications, a potential risk factor had to have an odds ratio with a 95% confidence interval, of which the lower limit was at least 1.
Results

Patients
Within the studied time period, intra-aortic balloon placement was attempted in 381 patients. A correct placement was not possible in eight patients so they did not undergo counterpulsation. In five other patients, the initial implantation attempt was unsuccessful, but placement was achieved using the contralateral femoral artery.
Of the 373 patients who were thus treated with intra-aortic balloon counterpulsation, 270 were in cardiogenic shock at the time of implantation. In these patients, mean duration of shock until intra-aortic balloon placement was 10·2 19·9 h (range 0·5 to 140 h; median 4 h). Prior to insertion of the intra-aortic balloon, inotropic agents were not used in 91 of the total 270 shock patients (34%). Low dose dopamine (up to 360 g . min 1 ) was used in 61 patients (23%), high dose dopamine (up to 1200 g . min 1 ) in 39 patients (14%), and epinephrine (with or without dopamine) was given in 79 patients (29%).
In another 13 patients, the intra-aortic balloon was used to wean patients from percutaneous cardiopulmonary bypass (following unsuccessful conventional cardiopulmonary resuscitation). Unstable angina was the reason for balloon placement in 55 patients (with bridging to surgery in 15 patients with left main stenosis and 17 patients with multiple vessel disease; bridging to angiography and/or revascularization in 10 patients with post-myocardial infarction angina, and 13 patients with post-myocardial infarction angina following angiography and/or PTCA). High-risk PTCA was the indication in another six patients, and 29 patients suffered from ischaemic left ventricular failure (15 patients with left main stenosis; 14 patients with multiple vessel disease). A total of 83 patients with acute myocardial infarction treated with an intra-aortic balloon had systemic thrombolysis, 65 of whom were in cardiogenic shock, nine had ischaemic left ventricular failure and another nine postmyocardial infarction angina pectoris. The clinical and procedural data of the patients are summarized in Table 1 .
The patients were assigned to three subgroups according to catheter size (12, 10·5 or 9·5 F). These subgroups did not differ significantly with respect to sex, age, frequency of cardiogenic shock, or cardiovascular risk factors.
In-hospital follow-up
Out of the 270 shock patients, 171 (63%) could be weaned from counterpulsation. In-hospital mortality was 58·5% (158/270) in the group of shock patients, 24% (7/29) in those with ischaemic left ventricular failure, 22% (12/55) in those with unstable angina, 33% (2/6) in those with high-risk PTCA and 85% (11/13) in those with percutaneous cardiopulmonary bypass support (PCPS) and weaning.
Intra-aortic balloon complications (Table 2)
Complications occurred in 48 of 373 patients (12·9%). In those surgically implanted (1977-1980; 12 F catheters) , the rate of complications was 30·4% (seven of 23 patients), and in those who underwent percutaneous implantation (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) it was 11·7% (41 of 350 patients). A percutaneous intra-aortic balloon counter- pulsation was associated with significant vascular injury (i.e. requiring surgical revision) in 19 patients (5·4%), and with limb ischaemia resulting in explantation of the catheter, or in fasciotomy for compartment syndrome in another 19 patients (5·4%). In 11 of these 19 patients with limb ischaemia following percutaneous intra-aortic balloon counterpulsation, the removal of the balloon catheter was performed surgically with additional thrombarteriectomy in seven patients. Leg amputation was required in two of these patients. In eight patients, the balloon was removed with manual compression without any further complications.
Bleeding from the insertion site, central or peripheral embolic events, or infections around the puncture site occurred in nine patients each (2·6% each).
Complications according to clinical and procedural factors, univariate analysis (Table 3, Figs 1 and 2)
For percutaneous intra-aortic balloon implantation, only peripheral vascular disease was significantly associated with a higher rate of complications in the univariate analysis (22·2%, P=0·038). The other potential risk factors (diabetes, nicotine use, sex, systemic hypertension, hyperlipoproteinaemia, manifest shock, age >70 years) had no statistically significant effect on the rate of complications. Patients with myocardial infarction who underwent systemic thrombolysis at the time of intraaortic balloon treatment were significantly less likely to develop intra-aortic balloon complications (four of 83 
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patients, 4·8%, P=0·023). In this group, complications were ischaemia in two (both in shock), vascular damage in one (shock), and bleeding in one (ischaemic left ventricular failure).
As demonstrated in Fig. 1 , the rate of complications was dependent on the duration of counterpulsation. When dividing the duration of intra-aortic balloon support into patient quartiles, complication rates were 8% in both the first and second quartiles, but twice that in both the third and fourth quartiles. The median of duration of couterpulsation in our group was 52·5 h. For further analyses, we chose a cut-off point of 48 h, which was considered a clinically meaningful value and potentially useful when applying the results of the present study to other patient populations.
When counterpulsation was employed for >48 h, the rate of complications was significantly higher (15·9%) than for shorter pump durations (6·4%, P=0·002) (Fig. 2) . Using thinner catheters appeared to reduce the risk of intra-aortic balloon-associated complications. The rate of complications was 20·7% (17 of 82 patients) for 12 F catheters, as compared with 9·9% (10 of 101 patients, P=0·04) for 10·5 F catheters, and 8·4% (14 of 167 patients, P=0·006) for 9·5 F catheters. When the 12 F subgroup was analysed separately, there was a significant association between intra-aortic balloon complications and the presence of peripheral vascular disease and diabetes mellitus in the univariate analysis. For the 9·5 F subgroup, on the other hand, only the association of nicotine use with intra-aortic balloon complications was (just) significant (Table 3) .
Complications according to clinical and procedural factors, multivariate analysis (Tables 4 and 5)
All patients with percutaneous intra-aortic balloon implantation were included in a stepwise multivariate logistic regression analysis. The potential covariables considered were age (>70 years), sex (female), peripheral vascular disease, systemic hypertension, hyperlipoproteinaemia, diabetes mellitus, nicotine use, shock, size of balloon catheter and duration of counterpulsation (>48 h). Four variables were independently predictive of intra-aortic balloon complications: longer duration of counterpulsation (odds ratio 3·6), catheter size (odds ratio for 12 F catheter 3·4), peripheral vascular disease (odds ratio 2·7), and shock (odds ratio 2·0). There was a trend towards an increased risk for female sex and systemic hypertension (Table 4) . When the analysis was repeated for ischaemic complications only, 12 F catheters, peripheral vascular disease, and shock were identified as independent risk factors. The duration of pumping was not significantly associated with this complication (Table 4) . After 1991, intra-aortic balloon implantations were performed exclusively with 9·5 F catheters. A subgroup analysis of all 167 patients treated using these thinner catheters revealed a strong independent association of intra-aortic balloon complications with only one factor, the duration of couterpulsation (odds ratio 3·8; Table 5 .
Discussion
Intra-aortic balloon complications
Widely differing rates of intra-aortic balloon-related complications have been reported in the literature, ranging from 5% to 47% [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . These discrepancies may be due to the varying definitions of events as intra-aortic balloon-associated complications. For the present study, only events which had direct consequences for the patient or for the management of the patient were considered. In accordance with previous studies, we found that ischaemia and vascular injury were the most frequent intra-aortic balloon-associated complications, with bleeding, embolic events, and infections occurring much less often [25] . The rate of intra-aortic balloon counterpulsation pump complications was reported to be high (42% and 47%, respectively) in two previous studies which compared 12 F and 10·5 F catheters, without a significant reduction of risk for thinner catheters [22, 23] . Kahn and co-workers subsequently studied the complications associated with the use of 10·5 F catheters in high-risk PTCA and reported a distinctly lower figure of 10·7% [11] . Another group recently published a rate of 12·9% (of which 4·6% were 'major complications') among 231 patients, using predominantly 9·5 F catheters [25] . The authors found a lower rate of limb ischaemia when using thinner catheters (8·1% for 8·5 or 9·5 F catheters) as compared to 10·5 F catheters (11·0%). These results show a trend similar to our data, which reveal a significant reduction of overall complications from 20% to 8·4% with the use of smaller-calibre catheters.
Predictors of intra-aortic balloon complications
At least nine different variables were identified as risk factors for intra-aortic balloon-related complications in previous studies. Only four of those were named in at least two studies, however: peripheral vascular disease, female sex, diabetes, and catheter size [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . The univariate analysis performed in the present study for percutaneous intra-aortic balloon implantation found a significant association between catheter size (12 F), peripheral vascular disease, and longer duration of counterpulsation with a higher complication rate. The risk for women, which was elevated in some studies [20] [21] [22] [23] , was increased only slightly and not significantly in the subgroup with larger (12 F) catheters in our study. The same applied to diabetes as a potential risk factor. When considering only 9·5 F catheters, the overall complication rate was distinctly lower (8·4%), and nicotine use the only factor associated with complications (just reaching statistical significance).
Surprisingly, systemic thrombolytic therapy was associated with a lower risk on account of the intraaortic balloon in our patients. As previously reported by Goodwin et al., an intra-aortic balloon may not increase bleeding complications and thus may be safe in patients receiving thrombolytic therapy [30] . In addition, on the one hand, thrombolysis may have protective effects regarding potential sheath-related thrombotic and embolic events, and on the other may have a positive influence on shock-induced microvascular injury, with its inherent local thrombogenesis leading to a lower rate of intra-aortic balloon-related ischaemia as compared to shock patients without thrombolysis. This effect may be pronounced in the present study since almost most of our patients were in cardiogenic shock.
Multivariate logistic regression analysis of percutaneously implanted intra-aortic balloons revealed two balloon-related independent predictors of complications, catheter size and duration of support, and two clinical predictors, peripheral vascular disease and manifest shock. When considering only 9·5 F catheters, the sole remaining independent risk factor for intra-aortic balloon complications was prolonged duration of counterpulsation, which has not been analysed in previous studies. In patients with 9·5 F catheters, in whom counterpulsation did not exceed 48 h, the complication rate was low at 3·9%, independent of the presence of other potential risk factors. This result may be of value when the intra-aortic balloon is considered for indications such as unstable angina or high-risk PTCA or prophylactic pumping in patients with myocardial infarction and successful revascularization. This is because the duration of counterpulsation in these cases is usually brief and it may be inferred that the risk associated with an intra-aortic balloon is then quite low. On the other hand, the duration of counterpulsation and its inherent risk should be considered when deciding whether to continue intra-aortic balloon treatment in patients with cardiogenic shock stabilized by an intra-aortic balloon.
Limitations of the study
The present study is a retrospective, single-centre analysis, with the inherent problems of such a design. In this aspect it is similar to almost all previously published reports on the topic. Errors in retrospectively recognizing complications were minimized by using only relevant complications which, by definition, would have an impact on the patient and his future management. The documentation of other data, such as potentially contributing risk factors (i.e. previous smoking history) may obviously be less complete.
Another potential problem is that intra-aortic balloon implantations at our hospital have steadily increased in frequency over the years. It may be concluded that the lower rate of risk associated with thinner catheters (which also reflect a later period of implantation) may simply mean that the indication for intraaortic balloon treatment was extended to less seriously ill patients. This is unlikely, however, since the subgroups of patients with catheters of different sizes did not differ with respect to clinical parameters. It cannot be excluded, however, that the complication rate was in part reduced because the cardiologists at our centre became more experienced over time.
Conclusions
The rate of intra-aortic balloon-related complications has decreased over the last few years and this appears to be related to the development of thinner catheters. The associated risk may now be deemed sufficiently low to use intra-aortic balloons in elective (non-emergency) situations. When 9·5 F catheters are employed, the only independent risk factor related to intra-aortic balloon complications is a prolonged duration of counterpulsation. Future studies will have to show whether even thinner catheters, combined with a sheathless implantation technique [31] , can reduce the rate of complications further.
